Upload
others
View
39
Download
1
Embed Size (px)
Citation preview
ONGC TERI Biotech Limited
1
8TH
ANNUAL REPORT
2014-2015
ONGC TERI Biotech Limited
AN ISO9001:2008;
14001:2004&18001:2007
CERTIFIED COMPANY
Reg. No. : RI91/7445
ONGC TERI Biotech Limited
2
BOARD OF DIRECTORS
Shri Ashok Varma Chairman
(DIN06909494)
Dr. Banwari Lal Director & CEO
(DIN 01139763)
Shri M.M.Joshi Director
(DIN 01139690)
Dr. D.M.Kale Director
(DIN 01129072)
Shri R.K.Sharma Director
(DIN 05345881)
STATUTORY AUDITORS
M/s Khanna & Annadhanam
Chartered Accountants,
New Delhi (Registration No: 01297N)
BANKERS
State Bank of Hyderabad,
Lodhi Road, New Delhi
REGISTERED OFFICE
ONGC TERI Biotech Limited
The Energy and Resources Institute,
Darbari Seth Block, IHC Complex,
Lodhi Road, New Delhi-110003
CIN: U74120DL2007PLC161117 Tel.: 011-24682300, 011-41504900
Fax: 011-24682144
Website: www.otbl.co.in
ONGC TERI Biotech Limited
3
NOTICE
NOTICE is hereby given that the 8th Annual General Meeting of the Members of ONGC TERI Biotech
Limited will be held on Wednesday, the 22nd July, 2015 at 17.30 Hrs. at 4th Floor, Conference Room,
TERI, Darbari Seth Block, IHC Complex, New Delhi-110003, to transact the following Ordinary
Business:
1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2015 and the Statement of
Profit and Loss and Cash Flow Statement of the Company for the financial year ended on that date
together with the Reports of the Directors‟ and the Auditors thereon.
2. To appoint a Director in place of Shri Ashok Varma (DIN: 06909494) who retires by rotation and
being eligible, offers himself for re-appointment.
3. To appoint a Director in place of Dr. Banwari Lal (DIN: 01139763) who retires by rotation and being
eligible, offers himself for reappointment.
4. To ratify appointment of Statutory Auditors, M/s Khanna and Annadhanam, Chartered Accountants,
(Regn. No.001297N), New Delhi, as required under section 139 of the Companies Act, 2013 read
with the Companies (Audit and Auditors) Rules 2014 and to authorize the Board of Directors to fix
their remuneration.
By Order of the Board of Directors
for ONGC TERI Biotech Limited
Sd/-
Place: New Delhi (Dr. Banwari Lal)
Dated: 22nd
July, 2015 Director &
CEO
(DIN 01139763)
NOTE:
1. A Member entitled to attend and vote at the meeting is entitled to appoint a Proxy to attend and vote instead of
himself and the Proxy need not be a Member of the Company. Proxies in order to be effective must be received by
the Company not less than forty-eight hours before the meeting.
ONGC TERI Biotech Limited
4
DIRECTORS’REPORT
Dear Members,
Your Directors are pleased to present the 8th Annual Report together with the Audited Accounts of the
Company for the period ending on 31st March, 2015.
Financial Results
The Company has followed the Project Completion method for recognizing revenue. Based on Projects
closed, your Company during the year has generated gross revenue of Rs.1, 937. 84 lakhs (Previous year -
Rs. 1,544.52 lakhs). After meeting the operational & other expenses, after tax carried forward net profit of
your Company is Rs. 451.38 lakhs (Previous year - Rs. 448.88 lakhs).
Dividend
Your Directors do not recommend payment of any dividend for the period ended 31st March, 2015.
Operations Highlights
Your Company which was set-up as a Joint-Venture of Oil and Natural Gas Corporation Ltd., (ONGC)
and The Energy and Resources Institute (TERI) continues to provide oil field services to the Oil and Gas
Industry using microbial methods primarily in four areas, namely:
1. Bio-remediation using Oilzapper Technology;
2. Microbial Enhanced Oil Recovery;
3. Application of Paraffin Degrading Bacteria (PDB) technology to prevent chocking of
Production Tubing; and
4. Wax Deposition Prevention (WDP) in flow lines.
Order Book
(i) Bioremediation Jobs
Your Company during the year successfully executed the Bio-remediation job by use of “Oilzapper”
Technology at following sites:
i) ONGC Mehsana Asset - 31,953 MT. of Oily Sludge
ii) ONGC Ahmedabad Asset - 36,000 MT. of Oily Sludge
iii) Reliance Industries Ltd. Nagothane - 500 MT. of Oily Sludge
iv) Numaligarh Refinery Ltd, Assam - 1,270 MT. of Oily Sludge
ONGC TERI Biotech Limited
5
Before Bioremediation After Bioremediation
The following work orders, which are under execution by your Company, were also received during the
year:
i) ONGC Ahmedabad Asset - 60,227 MT. of Oily Sludge
ii) ONGC Mehsana Asset - 42,827 MT. of Oily Sludge
iii) ONGC Agartala Asset - 500 MT. of Oily Sludge
iv) BPCL, Mumbai - 3,200 MT. of Oily Sludge
v) Reliance Industries, Mumbai - 1,000 MT. of Oily Sludge
ONGC TERI Biotech Limited
6
Before Bioremediation After Bioremediation
(ii) Microbial Enhanced Oil Recovery (MEoR)
Work Order for execution of Microbial Enhanced Oil Recovery (MEoR) job in 10 wells of ONGC,
Ankleshwar Asset received by your Company during the year was under execution.
Execution of MeOR job in oil wells
(iii) Wax Deposition Prevention (WDP)/ Paraffin Degrading Bacterial (PDB)
During the year, your Company successfully completed Paraffin Degrading Bacterial (PDB) jobs in 14
wells of ONGC, Ankleshwar Asset and in 45 wells of ONGC, Mehsana Asset. Out of a Work Order for
PDB jobs in 50 Wells received from ONGC, Ahmedabad Asset, PDB Job in 38 Wells was completed
during the year while the remaining jobs were under execution.
Execution of PDB job in Oil Wells
ONGC TERI Biotech Limited
7
Rate Contract
During the year, under the Long-term three years Rate Contract with ONGC, your Company received
work orders for Bioremediation of approximately 12,500 MT of oily sludge/oil soaked soil worth about
Rs. 3.20 Crore from various work centres of ONGC. These work orders are currently under execution.
Future Outlook
The order book of your Company continues to be overflowing with several proposals in pipeline and
nearing maturity.
ISO Certificate of Compliance
Your Company during the year successfully completed the initial Three Years period and the Certificate
for its Integrated Management System for „Providing & Promoting Biotechnological Solutions to Oil and
Gas Industry‟, being compliant with the requirements of International Standards of quality Management
System-ISO 9001:2008; Environmental Management System- ISO14001:2004 and Occupational Health
and Safety Management System-OHSAS18001:2007 was renewed by the International Certification
Services Pvt. Ltd.,(ICS) for a further period of Three years valid up to 15th March, 2018.
Authorization of Bioremediation Services by PCB, Assam
The Pollution Control Board, Assam has given authorisation under provisions of Rules5 (4) of Hazardous
Waste (Management, Handling & Transboudary Movement) Rules, 2008 for collection, reception,
treatment, transportation & storage of Hazardous Wastes (oily Sludge) during the Bio-remediation of
sludge pits at various sites throughout Assam, valid up to December,2016.
Deposits
The Company has not accepted any Deposits from the public in terms of Section 73 of the Companies
Act, 2013.
Meetings of the Board of Directors
During the year ended 31st March, 2015, the Board of Directors of your Company met four times. The
dates on which the Board meetings were held are 26th June, 29th September & 12th November, 2014 and
23rd February, 2015.
Auditors
M/s Khanna and Annadhanam, Chartered Accountants, New Delhi, (Regd. No.001297N), were
appointment as the Statutory Auditors of the Company from the conclusion of the 7th Annual General
Meeting until the conclusion of the 12th Annual General Meeting at such remuneration as to be fixed by
the Board of Directors. Their continued appointment is to be ratified by the Members at the ensuing 8th
Annual General Meeting.
There is no qualification in the Auditors‟ Report for the year ended 31st March, 2015.
ONGC TERI Biotech Limited
8
Particulars of Employees
There is no employee in the Company whose particulars are required to be given in terms of the
provisions of Section 197 of the Companies Act,2013 read with Rules 5 of the Companies (Appointment
and Remuneration of Managerial Personnel) Rules, 2014,
Particulars of Conservation of Energy, Technology Absorption, Foreign Exchange etc.
Your Company while providing bioremediation solutions to the Oil and Gas Industry is continuously
endeavouring to develop most energy efficient processes and devices. Wherever possible, energy
conservation measures have been implemented. Effort to conserve & optimize use of energy and absorb
new techniques is a continuous process in your Company. The Company earned and spent foreign
exchange equivalent to Rs. 8, 412, 265/- and Rs. 19, 080/-(Previous Year-Rs.22, 056), respectively
during the accounting period ended 31st March, 2015.
Directors’ Responsibility Statement
Pursuant to the requirement under Section 134 of the Companies Act, 2013, with respect to the Directors'
Responsibility Statement, the Board of Directors of the Company hereby confirms:
(i) that in the preparation of the Annual Accounts, the applicable accounting standards have been
followed;
(ii) that the accounting policies selected and applied are consistent and the judgment and
estimates made are reasonable and prudent so as to give a true and fair view of the state of
affairs of the Company at the end of the financial year and of the profit or loss of the
Company for that period;
(iii) that proper and sufficient care has been taken for the maintenance of adequate accounting
records in accordance with the provisions of the Companies Act, 2013 for safeguarding
the assets of the Company and for preventing and detecting fraud and other irregularities;
(iv) that the Annual Accounts have been prepared on a going concern basis;
(v) That the internal financial controls to be followed have been laid down which are adequate
and were operating effectively; and
(vi) That proper system has been devised to ensure compliance with the provisions of all
applicable laws and that such system was adequate and operating effectively.
Contracts and Arrangements with Related Parties
All contracts / arrangements / transactions entered by the Company during the financial year with related
parties were in the ordinary course of business and on an arm‟s length basis. There were no materially
significant related party transactions made by the Company which may have a potential conflict with the
interest of the Company at large.
ONGC TERI Biotech Limited
9
Your Directors draw attention of the members to Note 21 to the financial statement which sets out related
party disclosures.
Extracts of Annual Return
The Extracts of Annual Return is prepared in Form MGT-9 as per the provisions of the Companies Act,
2013 and Rule 12 of Companies (Management and Administration) Rules, 2014 and the same is enclosed
as Annexure to this Report.
Directors and Key Managerial Personnel
In accordance with the provisions of Section 152 of the Companies Act, 2013 and the Articles of
Association of the Company, Shri Ashok Varma (DIN 06909494) and Dr. Banwari Lal (DIN 01139763),
Directors retire by rotation and being eligible, offer themselves for re-appointment.
Acknowledgements
The Directors wish to thank and deeply acknowledge the co-operation, assistance and support extended
by ONGC, TERI and other shareholders, Company‟s bankers and Statutory Auditors etc. The Directors
also wish to place on record their appreciation of the contribution made at all levels by the employees of
your Company, and look forward to a long term future with confidence.
Regd. Office: On behalf of the Board of Directors
for ONGC TERI Biotech Limited The Energy and Resources Institute,
Darbari Seth Block, IHC Complex, Sd/-
Lodhi Road, New Delhi-110003
(Ashok Varma)
Date: 22nd
July, 2015 Chairman
(DIN: 06909494)
.
ONGC TERI Biotech Limited
10
Annexure to the Directors’ Report
Form No.MGT-9 EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED 31
st MARCH, 2015
[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014]
I. REGISTRATION AND OTHER DETAILS:
i) CIN : U74120DL2007PLC161117
ii) Registration Date : 26th March, 2007
iii) Name of the Company : ONGC TERI Biotech Limited
iv) Category/Sub-Category of the Company : Company Limited by Shares / Public
Company
v) Address of the Registered : The Energy and Resources Institute,
Office and contact details Darbari Seth Block, IHC Complex,
Lodhi Road, New Delhi-110003
Tel.: 011-24682300, 011-41504900
Fax: 011-24682144
Website: www.otbl.co.in
vi) Whether listed Company : No
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:
All the business activities contributing 10 % or more of the total turnover of the Company:
S. No. Name and Description of main NIC Code of the % to total turnover of the Company
Product/ Service Products /Services I. Bioremediation Services of Group: 99944 90%
Cleaning of Oil Contaminated Class:999441
Soil/Sludge Sub-Class : 9994413
III. PARTICUALRS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES: Nil
IV. Shareholding Pattern:
i) Category-wise Shareholding: Sl.
No.
Category of
Shareholders
No. of Shares held
at the beginning of
the year
% Share-
holding
No. of Shares
held at the end
of the year
% Share-
holding
% Change in
Shareholding
during the year
1. Promoters:
Bodies Corporate 49,000 98 49,000 98 -
2 Individuals 1,000 2 1,000 2 -
Total 50,000 100 50,000 100
ONGC TERI Biotech Limited
11
ii) Shareholding of Promoters: Sl.
No.
Shareholder’s
Name
No. of Shares held
at the beginning of
the year
% Share-
holding
No. of Shares
held at the end
of the year
% Share-
holding
% Change in
Shareholding
during the year
1 Oil and Natural
Gas Corporation
Ltd. (ONGC)
24,990 49.98 24,990 49.98 -
2 The Energy and
Resources
Institute(TERI)
24,010 48.02 24,010 48.02 -
Total 49,000 98 49,000 98 -
iii) Changes in Shareholding of Promoters during the year: No Change
iv) Shareholding Pattern of Top Ten Shareholders (Other than Directors & Promoters: Sl.
No.
Shareholder’s
Name
No. of Shares held
at the beginning of
the year
% Share-
holding
No. of Shares
held at the end
of the year
% Share-
holding
% Change in
Shareholding
during the year
1 Mr. S.K.C.Mathur 200 0.4 200 0.4 -
2. Mr. Albert Trevor 200 0.4 200 0.4 -
Total 400 0.8 400 0.8 -
v) Shareholding of Directors & Key Managerial Personnel (KMP): Sl.
No.
Shareholder’s
Name
No. of Shares held
at the beginning of
the year
% Share-
holding
No. of Shares
held at the end
of the year
% Share-
holding
% Change in
Shareholding
during the year
A. Directors:
1. Dr. Banwari Lal 200 0.4 200 0.4 -
2. Mr. R.K.Sharma 200 0.4 200 0.4 -
3. Dr.D.M.Kale 200 0.4 200 0.4 -
B. KMP: - - - - -
Total 600 1.2 400 1.2 -
V. Indebtedness:
Neither at the beginning nor at the end of the Financial Year, the Company had any debts, secured or unsecured.
VI. Remuneration of Directors & Key Managerial Personnel:
No Director or any Key Managerial Personnel were paid any remuneration during the Financial Year, except
Dr. D.M.Kale, who was paid Rs.15,000/- as sitting fees for attending meetings of the Board of Directors.
VII. Penalties/Punishment/Compounding of Offences, if any:
Type Section of The
Companies Act
Brief Description Details of Penalty / Punishment/
Compounding fees imposed
Authority [RD
/NCLT/COURT]
Appeal made,
if any
A. Company
Penalty
Punishment
Compounding
B. .Directors
Penalty
Punishment Compounding
C. Other Officers In
Default Penalty
Punishment
Nil
ONGC TERI Biotech Limited
12
Compounding
_______________________________________________________________________________________
Independent Auditor’s Report
To the Members of ONGC Teri Biotech Limited Report on the Financial Statements We have audited the accompanying Financial Statements of ONGC Teri Biotech Limited („the Company‟), which comprise the Balance Sheet as at March 31, 2015, the Statement of Profit and loss and the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information. Management’s Responsibility for the Financial Statements The Management and Board of Directors of the company are responsible for the matters stated in Section
134(5) of the Companies Act, 2013 (“the Act”) with respect to the preparation of these Financial
Statements that give a true and fair view of the financial position, financial performance and cash flows of
the Company in accordance with the accounting principles generally accepted in India, including the
Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies
(Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in
accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing
and detecting frauds and other irregularities; selection and application of appropriate accounting policies;
making judgments and estimates that are reasonable and prudent; and design, implementation and
maintenance of adequate internal financial controls, that are operating effectively for ensuring the
accuracy and completeness of the accounting records, relevant to the preparation and presentation of the
financial statements that give a true and fair view and are free from material misstatement, whether due to
fraud or error. Auditor’s Responsibility Our responsibility is to express an opinion on these Financial Statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the Audit Report under the provisions of the Act and the Rules made there under. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures
in the Financial Statements. The procedures selected depend on the auditor‟s judgment, including the
assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or
error. In making those risk assessments, the auditor considers internal financial control relevant to the
Company‟s preparation of the Financial Statements that give a true and fair view in order to design audit
ONGC TERI Biotech Limited
13
procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on
whether the Company has in place an adequate internal financial controls system over financial reporting
and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of
the accounting policies used and the reasonableness of the accounting estimates made by the Company‟s
Management and the Board of Directors, as well as evaluating the overall presentation of the Financial
Statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for
our audit opinion on the Financial Statement.
Opinion In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2015, its profit and its cash flows for the year ended on that date. Report on Other Legal and Regulatory Requirements
1. As required by the Companies (Auditor‟s Report) Order, 2015 (“the Order”) issued by the Central
Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters specified in the paragraph 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that: (a) We have sought and obtained all the information and explanations which to the best of our
knowledge and belief were necessary for the purposes of our audit. (b) In our opinion, proper books of account as required by law have been kept by the Company so far
as it appears from our examination of those books; (c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this
Report are in agreement with the books of account; (d) In our opinion, the aforesaid Financial Statements comply with the applicable Accounting
Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
(e) On the basis of the written representations received from the directors as on 31 March 2015 and
taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2015 from being appointed as a director in terms of Section 164 (2) of the Act; and
(f) In our opinion and to the best of our information and according to the explanations given to us, we
report as under with respect to other matters to be included in the Auditor‟s Report in accordance
with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:
i. The Company does not have any pending litigations which would impact its financial position ;
ii. The Company does not have any long term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise.
iii. There has not been an occasion in case of the company during year under report to transfer any
sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.
for Khanna & Annadhanam
ONGC TERI Biotech Limited
14
Chartered Accountants
(Registration No: 01297N)
Sd/-
(Kapil Miglani)
Place: New Delhi Partner
Date: 13th
May, 2015 (Membership No: 527679)
Annexure to the Independent Auditors’ Report
The Annexure referred to in Paragraph 1 of our Report of even date to the members of the Company on the Accounts for the year ended 31
st March 2015.
On the basis of such checks as we considered appropriate and according to the information and explanations given to us during the course of the Audit, we report that: (i) (a) The Company has maintained proper records showing full particulars, including quantitative
details and situation of fixed assets.
(b) As explained to us, fixed assets have been physically verified by the Management at regular
intervals: as informed to us no material discrepancies were noticed on such verification; (ii) The nature of business of the Company does not require it to have any inventory. Hence, the
requirement of clause (ii) of paragraph 3 of the said order is not applicable to the Company. (iii) The Company has not granted any loans, secured or unsecured to/from companies, firms or other
parties covered in the register maintained under section 189 of the Act.
(iv) In our opinion and according to the information and explanations given to us, there is an adequate
internal control system commensurate with the size of the Company and the nature of its business
with regard to purchase of fixed assets and sale of services. Further, on the basis of our examination
of books and records of the company and according to the information and explanations given to us,
no major weakness has been noticed or reported.
(v) The Company has not accepted any deposits from the public covered under Section 73 to 76 of the
Companies Act, 2013.
(vi) As informed to us, the Central Government has not prescribed the maintenance of cost records under
section 148(1) of the Act.
(vii) a) According to the information and explanations given to us and based on the records
of the Company examined by us, the Company is regular in depositing the undisputed
statutory dues including provident fund, income tax, sales tax, wealth tax, service tax,
duty of customs, excise duty, cess and other material statutory dues, as applicable, with
the appropriate authorities in India.
b) According to the information and explanations given to us and based on the records
of the Company examined by us, there are no dues of income tax, wealth tax, service tax,
sales tax, Custom duty and excise duty which have not been deposited on account of any
disputes.
c) There has not been any occasion in case of the company during the year under report to
transfer any sums to the Investor Education and Protection Fund. The question of
ONGC TERI Biotech Limited
15
reporting delay in transferring such sums does not arise.
(viii) The Company does not have any accumulated losses at the end of the financial year and has not
incurred cash losses in the financial year and in the immediately preceding financial year. (ix) According to the records of the Company examined by us and as per the information and explanation
given to us, the Company has not availed of any loans from any financial institution or banks and has not issued debentures.
(x) In our opinion and according to the information and the explanations given to us, the Company has
not given any guarantee for loans taken by others from banks or financial institutions during the year. (xi) In our opinion and according to information and explanation given to us, the Company has not raised
any term loans during the year. (xii) During the course of our examination of the books and records of the company, carried in accordance
with the auditing standards generally acceptable in India, we have neither come across any instance of fraud on or by the Company noticed or reported during the course of our audit nor have we been informed of any such instance by the Management
for Khanna & Annadhanam
Chartered Accountants
(Registration No: 01297N)
Sd/-
(Kapil Miglani)
Place: New Delhi Partner
Date: 13th
May, 2015 (Membership No: 527679)
ONGC TERI Biotech Limited
16
BALANCE SHEET AS AT 31ST MARCH, 2015
PARTICULARS
NOTE NO. CURRENT YEAR
(31.03.2015)
PREVIOUS YEAR
(31.03.2014)
I. EQUITY AND LIABILITIES
1 Shareholders’ funds
Share Capital 2 500,000 500,000
Reserve and Surplus 3 207,117,329 162,060,260
2 Non-current liabilities
Long-term Provisions
4
503,727
_
3 Current liabilities
Trade payables 27,964,808 27,846,418
Deferred tax liabilities (Net) _ _
Other current liabilities 5 260,009,279 179,400,844
Short term provisions 6 2,067,276 3,173,482
498,162,419 372,981,004
II. ASSETS
1 Non-current assets
Fixed Assets
- Tangible Assets 7 4,831,557 5,412,434
Deferred Tax Assets (Net) 230,578 85,788
Long Term Loan and Advances 8 3,976,823 3,914,709
2 Current assets
Trade Receivables 9 175,262,265 56,794,608
Cash and Cash Equivalents 10 173,883,587 165,585,675
Short Term Loan and Advances 11 20,253 18,253
Other Current Assets 12 139,957,356 141,169,537
498,162,419 372,981,004
Significant Accounting Policies 1
The accompanying Notes are significant part of the Financial Statements (16 to 24) As per our report of even date
For KHANNA & ANNADHANAM
CHARTERED ACCOUNTANTS
(Reg. No. 01297N)
Sd/- Sd/- Sd/- Sd/-
ONGC TERI Biotech Limited
17
(KAPIL MIGLANI) (H.C. CHAUHAN) (ASHOK VARMA) (BANWARI LAL)
Manager-F&A
(M. No. 527679)
CHAIRMAN
(DIN 06909494)
DIRECTOR & CEO
(DIN 01139763)
PLACE :NEW DELHI
DATED : 13th
May, 2015
PROFIT & LOSS STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2015
PARTICULARS NOTE
NO.
CURRENT YEAR
(31.03.2015)
PREVIOUS YEAR
(31.03.2014)
I. Revenue from projects closed 179,836,832 141,333,809
II. Other Income 13 13,947,694 13,118,233
III. Total Revenue (I+II) 193,784,526 154,452,042
IV. Expenses :
Costs on projects closed 90,300,551 69,645,916
Employee benefits expense
14 10,336,686
9,134,059
Administrative & Selling expenses
15 24,830,041
8,358,587
Depreciation
7 1,202,263
866,389
Total Expenses 126,669,541 88,004,951
V Profit / (Loss) before tax (III-IV) 67,114,984 66,447,091
VI Tax expense:
Current Tax
22,121,517
21,529,080
Deferred Tax Asset
( 144,790)
29,677
VII Profit / (Loss) after tax (V -VI) 45,138,257 44,888,334
VIII Earning Per Equity Share
Basic & Diluted 903 898
Significant Accounting Policies 1
The accompanying Notes are an integral part of the Financial Statements (16-24) As per our report of even date
for KHANNA & ANNADHANAM
CHARTERED ACCOUNTANTS
(Reg. No. . 01297N)
Sd/- Sd/- Sd/- Sd/-
(KAPIL MIGLANI) (H.C.CHAUHAN) (ASHOK VARMA) (BANWARI LAL)
ONGC TERI Biotech Limited
18
Manager-F& A
(M. No. 527679)
CHAIRMAN
(DIN 06909494)
DIRECTOR & CEO
(DIN 01139763)
PLACE :NEW DELHI
DATED : 13th
May, 2015
CASH FLOWS STATEMENT FOR THE PERIOD ENDED 31ST MARCH, 2015
PARTICULARS CURRENT
YEAR
(31.03.2015)
PREVIOUS
YEAR
(31.03.2014)
Cash Flow from Operating Activities
Net Profit after Tax 45,138,257 44,888,334
Adjustments for:
Depreciation 1,202,263 866,389
Operating Profit before working capital changes 46,340,521 45,754,723
Adjustments for:
(Increase) / Decrease in Current Assets (117,319,590) 5,046,537
Increase / (Decrease) in Current Liabilities 80,124,346 14,159,545
Deferred Tax Assets (144,790) 29,677
Net Cash from Operating Activities 'A' 9,000,487 9,000,487 64,990,482
Cash Flow from Investing Activities
Purchase of Fixed Assets (702,575) (1,460,090)
Net Cash utilised in Investing Activities 'B' (702,575) (1,460,090)
Cash Flow from Financing Activities
Net Cash utilised in Financing Activities 'C' - -
Net Increase / (Decrease) in Cash and Cash
Equivalents (A+B+C)
8,297,912 63,530,392
Opening Cash and Cash Equivalents 165,585,675 102,055,283
Closing Balance of Cash and Cash Equivalents 173,883,587 165,585,675
Cash and Cash Equivalents comprise:
Cash and Bank Balance 173,883,587 165,585,675
173,883,587 165,585,675
As per our report of even date
for KHANNA & ANNADHANAM
CHARTERED ACCOUNTANTS
(Reg. No. 01297N)
Sd/- Sd/- Sd/- Sd/-
(KAPIL MIGLANI) (H.C. CHAUHAN) (ASHOK VARMA) (BANWARI LAL)
Manager- F & A
(M. No. 527679)
CHAIRMAN
(DIN 06909494)
DIRECTOR & CEO
(DIN 01139763)
PLACE :NEW DELHI
ONGC TERI Biotech Limited
19
DATED : 13th
May, 2015
NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31
ST MARCH, 2015
1 SIGNIFICANT ACCOUNTING POLICIES
a)
Basis of Preparation
The Company has followed mercantile system of accounting and recognizes Income &
Expenditure on accrual basis. The accounts are prepared on historical cost basis, as a
going concern and are consistent with the generally accepted accounting principles.
b) Use of Estimates
The preparation of financial statements requires estimates and assumptions which affect
the reported amount of assets, liabilities, revenues and expenses of the reporting period.
The difference between the actual results and estimates are recognized in the period in
which the results are known or materialized.
c) Fixed Assets / Depreciation
d)
Fixed Assets are stated at historical cost less accumulated depreciation and impairment
loss, if any. Temporary site installations for execution of job are expensed as project
expenditure in the year in which they are incurred. Depreciation on Fixed Assets has been
provided on written down value basis according to the useful lives specified under
Schedule II of the Companies Act, 2013.
Impairment
The carrying amounts of assets are reviewed at each Balance Sheet date to assess
impairment, if any based on internal / external factors. An asset is treated as impaired when
the carrying cost of the asset exceeds its recoverable value being higher of value in use and
net selling price. An impairment loss is recognised as an expense in the Statement of Profit
& Loss in the year in which an asset is identified as impaired. The impairment loss
recognised in prior accounting period is reversed if there has been an improvement in
recoverable amount.
ONGC TERI Biotech Limited
20
e) Revenue Recognition
Revenue is recognised based on the nature of activity when consideration can be
reasonably measured and there exists reasonable certainty of its recovery. Revenue from
projects and costs are recognised based on substantial completion with the contractual
terms specified in the contract/agreement.
ONGC TERI Biotech Limited
21
f) Employee Benefits
g)
h)
i)
a) Employee benefits in the form of Provident Fund are charged to the Profit and Loss
Account of the year when the contributions to the respective funds are due. There are
no other obligations other than the contribution payable to the respective funds.
b) Gratuity liability is accrued and provided for on the basis of an actuarial valuation on
the projected unit credit method made at the end of the financial year.
c) Short term compensated absence are provided for based on estimates. Long term
compensated absences in the form of leave encashment are provided for based on
actuarial valuation at the end of the financial year. The actuarial valuation done as per
projected unit credit method.
d) Actuarial gains/losses are debited to profit and loss account and are not deferred.
Project Expenses
All direct expenses incurred towards execution of job as well as other general
administrative expenses incurred at site are allocated to the activities /job and charged
/treated in profit and loss statement accordingly.
Taxes on Income
a) Tax expense for the period, current tax and deferred tax is included in determining
the net profit (loss) for the period.
b) Deferred tax is recognised for all timing difference between the accounting income
and taxable income and is quantified using the enacted/substantially enacted tax rates
as at the balance sheet date.
c) Deferred Tax Assets are recognised where realisation is reasonably certain where as
in case of carried forward losses or unabsorbed depreciation, deferred tax assets are
recognised only if there is a virtual certainty of realisation backed by convincing
evidence. Deferred Tax assets are reviewed for the appropriateness of their respective
carrying value at each Balance Sheet date.
Provisions, Contingent Liabilities and Contingent Assets
Provisions involving substantial degree of estimation in measurement are recognized
when there is a present obligation as a result of past events and it is probable that there
will be an outflow of resources. Contingent Assets are neither recognized nor disclosed in
the financial statements.
ONGC TERI Biotech Limited
22
CURRENT YEAR PREVIOUS
YEAR
(31.03.2015) (31.03.2014)
2 SHARE CAPITAL
AUTHORISED
10,00,000 Equity Shares of Rs.10/- each 10,000,000 10,000,000
10,000,000 10,000,000
ISSUED, SUBSCRIBED AND PAID UP
50,000 Equity Shares of Rs.10/-each fully
paid up
500,000 500,000
500,000 500,000
The Company has issued only one class of shares referred to as equity shares having a par
value of Rs.10/-.
Each holder of equity shares is entitled to one vote per share.
Details of Equity Shareholders holding more than 5 percent Shares:
Oil and Natural Gas corporation ( ONGC) 24,990 24, 990
Percentage 49.98 49.98
The Energy and Resources Institute (TERI) 24,010 24,010
Percentage 48.02 48.02
3 RESERVES AND SURPLUS
Opening balance
Less: Adjustment towards depreciation
(Refer Note No.18)
162,060,260
81,188
117,171,926
_
Add: Net Profit/(Net Loss) for the current year 45,138,257 44,888,334
Closing balance 207,117,329 162,060,260
ONGC TERI Biotech Limited
23
4
LONG TERM PROVISIONS
Leave Encashment Payable
Gratuity Payable
CURRENT YEAR
(31.03.2015)
242,385
261,342
PREVIOUS YEAR
(31.03.2014)
-
-
503,727 -
5
OTHER CURRENT LIABILITIES
- Billing - Ongoing Projects
- Expenses Payable
- TDS Payable
- Employee contribution to Provident Fund
- Other Liabilities
258,930,076
769,177
287,420
21,606
1,000
178,498,137
618,252
263,091
20,364
1,000
260,009,279 179,400,844
6 SHORT TERM PROVISIONS
- Leave Encashment Payable
- Gratuity Payable
14,010
4,646
-
-
- Provision for Taxation 79,271,658
Less:- Advance Tax/TDS 77,223,038 2,048,620 2,657,422
- Service Tax payable - 516,060
2.067,276 3,173,482
8 LONG TERM LOANS AND ADVANCES
- Security Deposit Against Projects 3,913,473 3,851,359
- Security Deposit Others 63,350 63,350
3,976,823 3,914,709
ONGC TERI Biotech Limited
24
CURRENT YEAR
(31.03.2015)
PREVIOUS YEAR
(31.03.2014)
9 TRADE RECEIVABLES (Unsecured considered good)
Trade receivables exceeding six months
11,270,348
9,596,084
Others 163,991,917 47,198,524
175,262,265 56,794,608
10 CASH AND CASH EQUIVALENTS
- Cash-in-Hand
715
715
- Balance with Scheduled Bank 2,90,619 2,776,538
- Fixed Deposit
- held as margin money 50,487,554 40,605,756
- others 123,104,699 122,202,666
173,883,587 165,585,675
11 SHORT TERM LOANS AND ADVANCES
(Unsecured considered good)
- Advance to Suppliers/Others - -
- Advance to Staff 20,253 18,253
20,253 18,253
12 OTHER CURRENT ASSETS
- Expenses- Ongoing Projects 128,417,734 125,795,529
- Tax Deducted at Source (against ongoing
projects)
6,716,829 6,076,669
- Income Tax Refundable 438,151 438,151
- Interest accrued on Fixed Deposit 4,225,067 8,803,026
- Prepaid Expenses
- Cenvat Credit
59,550
1,00,025
56,162
-
139,957,356 141,169,537
ONGC TERI Biotech Limited
25
CURRENT YEAR PREVIOUS
YEAR
(31.03.2015)
(31.03.2014)
13 OTHER INCOME
- Interest on Fixed Deposit
- Liabilities no longer required written back
13,792,086
155,608
13,118,233
-
13,947,694 13,118,233
14 EMPLOYEE BENEFITS EXPENSES
Staff salary, allowances and reimbursement 8,995,866 8,391,340
Employer's contribution to PF and admin.
Charges
314,868 269,150
Group Insurance 289,657 292,307
Staff Welfare
- Leave Encashment Expenses
- Gratuity Expenses
213,912
256,395
265,988
181,262
-
-
10,336,686 9,134,059
15 OTHER EXPENSES
Web development & Maintenance Charges
5,356
34,933
Rent-Project / Site office 674,095 650,068
Books & Periodicals 3,332 10,038
Telephone/Internet Expenses 136,668 130,636
Courier charges 40,936 78,366
Electricity charges 79,683 68,563
Professional / Consultancy/legal fees 3,134,403 2,471,730
Travelling & Conveyance 3,096,611 2,839,697
Vehicle Running and Maintenance Expenses 305,865 328,873
Bank Charges 457,629 2,36,421
Miscellaneous / Sundry Expenses 18,918 37,894
Printing Stationery & Computer supplies 151,503 153,993
Repair & Maintenance-Others 232,240 862,683
Taxes & Fees 7,563 21,558
Advertisement, Publicity & Business Promotion 231.361 201,784
Auditors Remuneration 147,117 231,350
Service Tax paid for earlier years (including
interest)
16,106,761 -
ONGC TERI Biotech Limited
26
24,830,041 8,358,587
CURRENT YEAR PREVIOUS YEAR
(31.03.2015)
(31.03.2014)
16 CONTINGENT LIABILITIES
Claims against the company not
acknowledged as debts
i) Outstanding performance guarantees 37,403,4018 36,534,875
issued by the company bankers
(secured against Fixed Deposits under
Lien)
ii) Estimated amount of contracts remaining
to be executed to the Capital Account (net
of advances)
iii) Tax demand under disputes 7,572,050 -
(Also Refer Point (a))
37,403,418
-
7,572,050
36,534,875
-
-
44,975,468 36,534,875
Additional Information
(a) The department has on conclusion of assessment for A.Y. 2012-13 and vide intimation
under section 143(1) for A.Y. 2013-14 raised demands aggregating to 75.72 lacs
(including interest) against which no provision exists since the demand has come to be
raised owing to short allowance of taxes deducted at source. For the A.Y. 2012-13,
rectification application has been filed on 9th
March 2015 which is pending. For the A.Y.
13-14, similar action is proposed. There is no likelihood of any liability of the company
on this account.
17 Disclosure for Gratuity and Leave Benefit plans
The company has a defined benefit gratuity plan. The present value of obligation is
determined based on actuarial valuation using the projected unit method, which
recognizes each period of services as giving rise to additional unit of employee benefit
entitlement and measures each unit separately to build up the final obligation. The
obligation for leave encashment is recognized in the same manner as gratuity.
(i) Changes in the present value of defined benefit obligations are as under:
Particulars Gratuity Leave Encashment
2014-15 2013-14 2014-15 2013-14
Opening defined benefit - - - -
Interest cost/ current year 265,988 - 256,395 -
Annual return on plan assets - - - -
Benefit paid - - - -
Actuarial gain/loss on - - - -
ONGC TERI Biotech Limited
27
Closing defined benefit obligation 265,988 - 256,395 -
(ii) Changes in the fair value of plan assets are as follows:
Particulars Gratuity Leave Encashment
2014-15 2013-14 2014-15 2013-14
Opening fair value of plan assets - - - -
Expected returns - - - -
Contributions by employer - - - -
Benefit paid - - - -
Actuarial gain/losses - - - -
Closing fair value of plan assets - - - -
(iii) Net employee benefit expense debited to Profit and Loss Account:
Particulars Gratuity Leave Encashment
2014-15 2013-14 2014-15 2013-14
Interest cost/ current year 265,988 - 256,395 -
Expected return on plan assets - - - -
Actuarial gain/loss on - - - -
Net benefit expense to P&L 265,988 - 256,395 -
Actual return on plan assets - - - -
(iv) Actuarial Assumptions:
Particulars Gratuity Leave Encashment
2014-15 2013-14 2014-15 2013-14
Mortality Table IALM-
2006-08
- IALM-
2006-08
-
Discount Rate 7.75% - 7.75% -
Expected rate of return on plan - - - -
Rate of escalation in salary per 5.25% - 5.25% -
The estimates of future salary increase considered in actuarial valuation take into account
the inflation, seniority, promotion and other relevant factors such as demand in the
employment market and supply.
ONGC TERI Biotech Limited
28
18 DEPRECIATION
During the year ended 31st March 2015, the company had revised useful lives of its fixed
assets in line with the lives prescribed in Schedule II of the Companies Act, 2013.
Consequent to the re-working and re-alignment with the lives prescribed for various assets,
the depreciation expense for the year ended 31st March, 2015 is higher by Rs. 3, 21,686.
For assets whose life has been completed as on 31st March, 2014, the carrying value of
those assets amounting to Rs. 81,188 has been adjusted against the brought forward reserve
and surplus.
19 JOINT VENTURES / ASSOCIATES
The Company is a joint venture company formed by Oil and Natural Gas Corporation
Limited in association with The Energy and Research Institute, New Delhi (a Society
formed and registered in Societies Registration Act, 1860).
20 CONFIRMATION OF BALANCES
(a) Balance in Fixed Deposits account (including interest accrued) when compared to the
balance as reflected in the bank certificates issued by the bankers revealed a difference
of Rs. 13,38,759 which is under reconciliation for effecting appropriate adjustment. The
management is confident that the impact thereof on the accounts will not be material.
(b) Interest Income has been accounted for based upon the certificate issued by the bankers.
(c) The balances in parties‟ accounts as at 31st March, 2015 are subject to confirmation/
reconciliation in some of the cases. Adjustments, if any, upon due reconciliation thereof
is proposed to be accounted for in future. The management, however, is of the view that
the impact of adjustment entries, if any, would not be significant.
ONGC TERI Biotech Limited
29
21 RELATED PARTY DISCLOSURES
Key Managerial Personnel (KMP)
Dr. Banwari Lal (C.E.O)
Investing Entities (JV Partners)
Oil and Natural Gas Corporation Ltd. (ONGC)
The Energy & Resources Institute, New Delhi (TERI)
Details of Transactions
Transactions Joint Ventures KMP
CURRENT
YEAR
PREVIOUS
YEAR
CURRENT
YEAR
PREVIOUS
YEAR
Services Provided:
ONGC
(based on invoicing)
260,974,788 153,297,956 Nil Nil
Purchases /Services availed:
TERI
(based on invoicing)
51,553,413 59,332,854 Nil Nil
ONGC (Rent) 313,005 309,118 Nil Nil
Electricity Charges
Paid
62,248 58,174 Nil Nil
Amount Receivable:
ONGC Ltd. 163,359,060 47,410,116 Nil Nil
Amount Payable
TERI 10,665,500 15,551,115 Nil Nil
Key Management Personnel
No remuneration was paid to key management personnel during current as well as previous
year.
ONGC TERI Biotech Limited
30
CURRENT YEAR PREVIOUS YEAR
(31.03.2015)
(31.03.2014)
22 AUDITOR’S REMUNERATION
The details of Auditors remuneration is as under:
Audit Fees 75,000
117,500
Certification work & other services 47,700
81,500
Out of Pocket Expenses & Service Tax 24,417
32,350
23 EXPENDITURE INCURRED IN FOREIGN CURRENCY
Receipts in Foreign Currency 8,412,265 -
Expenditure in Foreign Currency (Travel) 19,080
22,056
24 Previous Year‟s figures have been regrouped / rearranged to make them comparable with the
current year‟s figures.
As per our report of even date
For KHANNA & ANNADHANAM
CHARTERED ACCOUNTANTS
(Firm Reg. No: 01297N)
Sd/- Sd/- Sd/- Sd/-
(KAPIL MIGLANI) (H.C.CHAUHAN) (ASHOK.VARMA) (BANWARI LAL)
Manager- F & A
M. No : 527679
CHAIRMAN
(DIN 06909494)
DIRECTOR &CEO
(DIN 01139763)
Place : New Delhi
Date : 13th
May,2015
147,117 231,350
8,431,345 22,056
ONGC TERI Biotech Limited
31
NOTE-7
Fixed Asset Schedule as on 31.03.2015
Particulars Gross Block Depreciation Net Block
As on
31.03.2014
Additions
during
the
period
Deletions/
Adjustment
during the
period
As on
31.03.2015
Up to
31.03.2014
For the
Period
Adjustment
during the
period
Up to
31.03.2015
As on
31.03.2014
As on
31.03.2015
Computer
845,589
234,902
431,037
649,454
544,917
194,368
349,848
389,437
300,672
260,017
Equipment
and Field
Installations
7,245,054
467,673
_
7,712,727
2,346,491
946,446
-
3,292,937
4,898,563
4,419,790
Furniture
373,191
_
_
373,191
159,991
61,449
-
221,441
213,199
151,750
TOTAL
8,463,834
702,575
431,037
8,735,372
3,051,400
1,202,263
349,848
3,903,816
5,412,434
4,831,557
P .Year
7,003,744
1,460,090
-
8,463,834
2,185,011
866,389
-
3,051,400
4,818,733
5,412,434